Research and development

The fields of research and development at riboxx relate to design, engineering and manufacturing of RNA for R&D and clinical trials. These activities aim at developping novel drugs for treatment of cancer, infectious diseases and degenerative diseases.
The scientists at riboxx have more than 15 years expertise in the field of cancer immunotherapy, as the initial scientific work in this field dealt with the detetion and characterization of tumor-specific antigens such as survivin [1].

Riboxx has acquired grants from the German Ministry of Research and Education (BMBF), from the Germany Ministry of Economy and Innovation (BMWI), from the Saxon Bank for Development (Sächsiche Aufbaubank), and was partner in two FP7-founded projects (SILVER and EUVIRNA).


1. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000 Apr 1;60(7):1815-7.


Intellectual property

The IP portfolio of Riboxx relates to various technologies focussing on design, engineering and manufacturing of RNA. The IP portfolio of Riboxx includes 17 international patent families as well as many brands among them riboxx®, RNA in a box®, RNA interference in a box®, iBONi®, iVORi®, TENPORA®, ENOVA®, CONTRAmir®, pre-CONmir®, CONmir®, and RIBOXXIM®.

© copyright Riboxx GmbH - all rights reserved